Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Mounjaro (tirzepatide) is a dual GLP-1/GIP agonist FDA-approved for type 2 diabetes; use for weight loss is off-label. Common side effects are nausea, vomiting, diarrhea, constipation, and stomach pain. Rare but serious risks include pancreatitis, gallbladder disease, kidney injury, thyroid C-cell tumors, severe allergy, and hypoglycemia with certain diabetes medicines [1].
What is Mounjaro and how does it work in the body?
Mounjaro is the brand name for tirzepatide, a dual GLP-1 receptor agonist and GIP receptor agonist made by Eli Lilly. It is FDA-approved to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise [1]. Use of Mounjaro for weight loss is off-label; Zepbound is the tirzepatide brand FDA-approved for chronic weight management in eligible adults [2].
Tirzepatide as a GLP-1 and GIP dual agonist
Tirzepatide works on two incretin hormone pathways: GLP-1 and GIP. These signals help the body release insulin when glucose is high, reduce glucagon, slow stomach emptying, and affect appetite pathways in the brain [1,3]. These same effects help explain both weight-loss results seen in trials and side effects such as nausea, reflux, constipation, and vomiting [3]. Individual results vary.
Why the mechanism drives most side effects
Because tirzepatide delays gastric emptying, food may stay in the stomach longer. That can lead to fullness, bloating, nausea, vomiting, reflux, or abdominal discomfort [1]. This delayed emptying is also why clinicians ask about severe gastrointestinal disease, gastroparesis, and procedures that require fasting or anesthesia [1,12].
| Medication | Generic | Drug class | FDA-approved use | Key side-effect overlap |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | Dual GLP-1/GIP agonist | Type 2 diabetes | Nausea, diarrhea, vomiting, constipation, abdominal pain, and hypoglycemia risk with insulin or sulfonylureas [1] |
| Zepbound | Tirzepatide | Dual GLP-1/GIP agonist | Chronic weight management in eligible adults | Same active ingredient as Mounjaro, with overlapping GI effects and warnings [2] |
| Ozempic | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes and cardiovascular risk reduction in certain adults | GI effects and boxed thyroid C-cell tumor warning in the label [9] |
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic weight management and cardiovascular risk reduction in certain adults | GI effects and boxed thyroid C-cell tumor warning in the label [10] |
| Compounded tirzepatide | Tirzepatide | Compounded GLP-1/GIP formulation | Not FDA-approved | Drug-related risks may overlap with tirzepatide, but compounded products are not FDA-reviewed for safety, effectiveness, or quality [6] |
What are the most common side effects of Mounjaro for weight loss?
The most common Mounjaro side effects are digestive. In the FDA label, adverse reactions reported in at least 5% of people receiving tirzepatide included nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain [1]. These effects should be weighed against possible weight and glucose benefits, plus serious warnings and contraindications [1,2].
| Side effect | How it may feel | Why it can happen | When to contact a clinician |
|---|---|---|---|
| Nausea and vomiting | Queasy stomach, gagging, throwing up | Slower stomach emptying and appetite signaling [1] | If vomiting is severe, persistent, or causes dehydration [1] |
| Diarrhea | Loose or frequent stools | Gut motility changes during treatment [1] | If diarrhea is severe, bloody, or linked with dizziness or low urination [1] |
| Constipation | Hard stools, straining, bloating | Slower gut movement and lower food intake [1] | If constipation is severe or paired with intense abdominal pain [1] |
| Heartburn, reflux, bloating | Burning, burping, pressure, fullness | Delayed gastric emptying can worsen upper-GI symptoms [1] | If symptoms are new, severe, or do not improve [1] |
| Injection site reactions | Redness, itching, or soreness where injected | Local skin response after injection [1] | If swelling spreads, hives occur, or breathing changes [1] |
| Fatigue and dizziness | Low energy or lightheadedness | Lower intake, dehydration, or glucose changes may contribute [1] | If fainting, confusion, or signs of low blood sugar occur [1] |
Nausea and vomiting
Nausea is one of the best-known tirzepatide side effects. In clinical trials summarized in the Mounjaro label, nausea and vomiting were common adverse reactions, and some participants stopped treatment because of GI effects [1]. Severe vomiting can lead to dehydration and kidney problems, so it should not be ignored [1].
Diarrhea and constipation
Both diarrhea and constipation can occur with tirzepatide. This may sound confusing, but GLP-1/GIP medicines affect gut movement, appetite, and how quickly food leaves the stomach [1]. Call a clinician if diarrhea or constipation is severe, prolonged, or paired with strong belly pain, fever, faintness, or low urine output [1].
Heartburn, reflux, and bloating
Tirzepatide can delay gastric emptying, which may make some people feel full faster or feel bloated after meals [1]. This effect has been studied as part of how tirzepatide may support weight loss, but it can also worsen reflux-like symptoms and may be a concern in people with severe GI disease, including severe gastroparesis [1,3].
Injection site reactions
Injection site reactions can include redness, itching, or soreness where the medicine is injected. The FDA label lists injection-site reactions among adverse reactions seen with tirzepatide [1]. Widespread hives, swelling of the face or throat, trouble breathing, or a fast heartbeat may signal a serious allergic reaction and needs urgent care [1].
Fatigue and dizziness
Fatigue or dizziness may happen if a person eats much less, becomes dehydrated, or has blood sugar changes. Tirzepatide can increase the risk of hypoglycemia when used with insulin or sulfonylureas, so clinicians may need to adjust diabetes medicines [1,11]. Symptoms such as shaking, sweating, confusion, or fainting should be taken seriously [1].
How bad are Mounjaro side effects, and how long do they last?
For many people, tirzepatide side effects are mild to moderate and more noticeable during treatment start or dose increases. In the Mounjaro FDA label, the FDA-approved starting dose for glycemic control is 2.5 mg once weekly for 4 weeks, followed by labeled stepwise increases when clinically appropriate [1]. That is label information, not personal dosing advice.
What clinical trials show about frequency and severity
In SURMOUNT-1, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks; gastrointestinal adverse events were the most common and were usually mild to moderate, mainly during dose escalation [3]. The trial also reported greater average weight loss with tirzepatide than placebo, but benefits came with side effects and trial exclusions, so results do not predict an individual outcome [3].
In SURPASS-2, adults with type 2 diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or semaglutide 1 mg once weekly for 40 weeks; tirzepatide reduced A1C and body weight more than semaglutide in that trial, while nausea, diarrhea, and vomiting were common in both groups [5]. People with certain risk factors may not match trial participants, and contraindications still apply [1,5].
Timeline: starting dose, titration, and adjustment
Side effects often cluster around treatment start and dose escalation because the gut is adapting to delayed stomach emptying and changed appetite signals [1,3]. FDA-labeled tirzepatide products use gradual titration schedules to improve tolerability, but the right plan depends on a person’s health history, other medicines, and adverse effects [1,2].
What are the serious risks I should know about?
Serious tirzepatide risks are uncommon but important. The Mounjaro label warns about pancreatitis, gallbladder disease, acute kidney injury, severe allergic reactions, hypoglycemia with insulin or sulfonylureas, and a boxed warning for thyroid C-cell tumors; these risks apply even when the goal is weight loss rather than blood sugar control [1].
Pancreatitis
Acute pancreatitis has been observed with GLP-1 receptor agonists and is included in the Mounjaro warnings [1]. Severe belly pain that may move to the back, with or without vomiting, needs prompt medical attention [1]. The label says tirzepatide has not been studied in people with a history of pancreatitis, so that history should be discussed before treatment [1].
Gallbladder disease and gallstones
Tirzepatide use has been associated with acute gallbladder disease, including gallstones and gallbladder inflammation [1]. Weight loss itself can also increase gallstone risk, so right-upper-belly pain, fever, yellowing skin, or pale stools should be reported quickly [1,2].
Acute kidney injury from dehydration
The Mounjaro label reports acute kidney injury and worsening chronic kidney failure, sometimes in people who had nausea, vomiting, diarrhea, or dehydration [1]. This is why severe GI symptoms are not just uncomfortable; they can become medically important, especially in people with kidney disease or medicines that affect fluid balance [1].
Thyroid C-cell tumor warning (boxed warning)
Mounjaro carries an FDA boxed warning because tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes medullary thyroid carcinoma in humans [1]. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 [1].
Severe allergic reactions
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [1]. Seek urgent care for trouble breathing, swelling of the face or throat, severe rash, fainting, or a fast heartbeat after an injection [1].
Hypoglycemia when combined with insulin or sulfonylureas
Tirzepatide can raise hypoglycemia risk when used with insulin or insulin secretagogues such as sulfonylureas [1]. This matters most for people with diabetes, and clinicians may consider lowering those medicines to reduce low-blood-sugar risk [1,11].
Who should not take Mounjaro?
Mounjaro is not appropriate for everyone. The FDA label lists contraindications and warnings, and a clinician should screen for them before prescribing [1]. Weight-loss interest alone is not enough to determine eligibility, because MTC or MEN 2, pancreatitis history, severe GI disease, pregnancy plans, and current medicines can change the risk-benefit balance [1,2].
Personal or family history of medullary thyroid carcinoma or MEN 2
People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia type 2, should not use Mounjaro or Zepbound [1,2]. This is a labeled contraindication, not a preference or caution [1].
History of pancreatitis or severe GI disease
The Mounjaro label notes that tirzepatide has not been studied in people with a history of pancreatitis [1]. It also warns that tirzepatide is not recommended in people with severe gastrointestinal disease, including severe gastroparesis, because it can cause GI adverse reactions and delays stomach emptying [1].
Pregnancy and breastfeeding considerations
Zepbound’s label says weight loss offers no benefit during pregnancy and may cause fetal harm [2]. Data are limited for breastfeeding, so pregnancy plans, contraception, and lactation should be discussed with a clinician before starting tirzepatide [1,2].
How can I manage or reduce side effects?
Side-effect management starts with telling your clinician what is happening, especially during the first 4 weeks or after a labeled dose increase [1]. Do not change your dose schedule on your own. Your clinician may adjust timing, evaluate hydration, review other medicines, or decide whether tirzepatide should be paused or stopped [1,2].
Eating and hydration strategies
- Eat smaller meals if fullness or nausea is a problem, and stop when comfortably full.
- Choose lower-fat, easier-to-digest foods during nausea flares; high-fat meals can worsen reflux or queasiness for some people.
- Sip fluids regularly, especially if vomiting or diarrhea occurs, because dehydration can raise kidney-injury risk [1].
- Ask a clinician before using over-the-counter nausea, reflux, diarrhea, or constipation medicines, especially with diabetes, kidney disease, or other prescriptions.
Dose titration and timing
The FDA labels for tirzepatide products use gradual titration schedules to help tolerability, but those schedules are not instructions for an individual reader [1,2]. If side effects are hard to manage, contact the prescriber rather than skipping, doubling, or changing doses on your own [1].
When to call your clinician vs. seek urgent care
| Situation | What to do | Why it matters |
|---|---|---|
| Mild nausea, reflux, constipation, or diarrhea | Message or call your clinician if it lasts or affects eating and drinking | These are common but may need treatment adjustment [1] |
| Repeated vomiting, dizziness, very low urine, or inability to keep fluids down | Call promptly or seek urgent care | Dehydration can contribute to acute kidney injury [1] |
| Severe belly pain, especially going to the back | Seek urgent medical care | This can be a pancreatitis warning sign [1] |
| Trouble breathing, throat swelling, widespread hives, fainting | Seek emergency care | These can be signs of severe allergic reaction [1] |
| Shaking, sweating, confusion, or fainting in a person using insulin or sulfonylureas | Treat as possible hypoglycemia and contact a clinician | Tirzepatide can increase low-blood-sugar risk with these medicines [1] |
Do you gain weight back after stopping Mounjaro?
Weight regain can happen after stopping tirzepatide. In SURMOUNT-4, participants first received open-label tirzepatide for 36 weeks, then were randomized to continue tirzepatide or switch to placebo for 52 weeks; people who switched to placebo regained weight on average, while those continuing tirzepatide lost more weight on average [4]. Individual results vary, and side effects, contraindications, cost, access, and personal goals all matter [1,4].
What the SURMOUNT data show
SURMOUNT-4 supports the idea that obesity can require ongoing management for many people, similar to other chronic conditions [4,8]. It does not mean every person should stay on tirzepatide long term. Long-term decisions must consider adverse effects, pregnancy plans, gallbladder symptoms, pancreatitis risk, and thyroid-cancer contraindications [1,2,4].
Planning a maintenance strategy with a clinician
A maintenance plan may include nutrition support, activity, sleep, mental health care, monitoring of side effects, and a medication plan if appropriate [8]. If tirzepatide is stopped, a clinician can help plan follow-up so weight, blood sugar, blood pressure, and symptoms are watched safely [8,11].
Is Mounjaro safe for weight loss if it's prescribed off-label?
Mounjaro for weight loss is off-label because Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for chronic weight management in eligible adults [1,2]. Off-label prescribing can be legal when a licensed clinician judges it medically appropriate, but the discussion should cover expected benefits, GI side effects, serious warnings, contraindications, alternatives, and the same active ingredient in Zepbound [1,2].
Mounjaro vs. Zepbound: same drug, different indication
Mounjaro and Zepbound both contain tirzepatide, so their side-effect and warning profiles overlap. The key difference is the FDA-approved indication: Mounjaro is labeled for adults with type 2 diabetes, while Zepbound is labeled for chronic weight management in eligible adults [1,2].
Compounded tirzepatide via 503A pharmacies: what to know
Compounded tirzepatide is not FDA-approved. A licensed 503A compounding pharmacy may prepare patient-specific medicines under federal and state rules, but compounded products are not reviewed by FDA for safety, effectiveness, or quality before they are dispensed [6]. Availability and legality can depend on federal shortage status, state pharmacy law, and FDA enforcement policy [6,7].
How to get a clinician-reviewed prescription for tirzepatide
A safe path starts with a medical review, not a shopping cart. A clinician should review BMI or weight-related conditions, diabetes status, medicines, kidney and gallbladder history, pregnancy plans, pancreatitis history, and contraindications such as MTC or MEN 2 before considering tirzepatide, including any discussion of compounded options [1,2,6,8].
Options may include an in-person clinician, an obesity-medicine specialist, an endocrinologist, or a licensed telehealth provider. Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1/GIP treatment when appropriate, using licensed 503A pharmacy partners; compounded tirzepatide is not FDA-approved and should be considered only after a clinician explains risks, alternatives, and current legal availability [6,7].
3-min quiz
Considering tirzepatide?
A licensed clinician can review your health history, current medicines, and contraindications before discussing FDA-approved and compounded options.
Frequently asked questions
The most common side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These are listed in the FDA label and are often gastrointestinal because tirzepatide slows stomach emptying and affects appetite signaling [1].
Clinical trials reported that GI effects were usually mild to moderate and often occurred during dose escalation [3]. Some people improve as the body adjusts, but severe, persistent, or dehydration-related symptoms need clinician review [1].
Do not stop or change tirzepatide on your own unless you are having an emergency. Seek urgent care for severe abdominal pain, signs of pancreatitis, trouble breathing, throat swelling, fainting, or severe dehydration. Call your prescriber for persistent vomiting, diarrhea, constipation, dizziness, or low-blood-sugar symptoms [1].
Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for chronic weight management in eligible adults. Because the active ingredient is the same, many side effects and warnings overlap [1,2].
Yes. Compounded tirzepatide is not FDA-approved, but because it is intended to contain tirzepatide, clinicians generally discuss similar drug-related risks such as nausea, vomiting, diarrhea, constipation, pancreatitis warnings, gallbladder disease, hypoglycemia risk with certain diabetes medicines, and thyroid C-cell tumor contraindications [1,6]. Product quality can vary if a pharmacy is not operating legally, so use licensed medical and pharmacy care only [6,7].
Some do. In SURMOUNT-4, people who switched from tirzepatide to placebo regained weight on average, while those who continued tirzepatide lost more weight on average. Individual results vary, and any long-term plan should weigh benefits against side effects, contraindications, cost, and preferences [4].
People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should not use Mounjaro or Zepbound [1,2]. A clinician should also review pancreatitis history, severe gastrointestinal disease, pregnancy plans, breastfeeding, kidney risk, gallbladder symptoms, and medicines that can cause hypoglycemia [1,2].
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still needs to review eligibility, risks, contraindications, and whether an FDA-approved or compounded option is appropriate.
3-min quiz
Talk with a clinician about GLP-1/GIP options
If you are weighing Mounjaro, Zepbound, or compounded tirzepatide, a clinician can help you compare benefits, side effects, contraindications, and access options.
References
- 1.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2024.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 4.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- 5.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 7.U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2024.
- 8.Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
- 9.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2024.
- 10.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 11.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024.
- 12.American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists. 2023.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
